title: Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.
abstract: Tumor-associated macrophages (TAMs) are a major cellular component of numerous tumor types. TAM-targeted therapies include depletion strategies, inhibiting their effector functions or reprogramming toward an antitumorigenic phenotype, with varying degrees of efficacy. Here, we review preclinical and clinical strategies to target macrophages in cancer and discuss potential explanations for why some strategies are effective while other approaches have shown limited success.Clin Cancer Res; 23(4); 876-84. ©2016 AACR.
authors.affiliation: Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.|Goodman Cancer Research Centre, Department of Physiology, McGill University, Montréal, Quebec, Canada.
authors.forename: Daniela F
authors.initials: DF
authors.lastname: Quail
authors.affiliation: Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland. johanna@joycelab.org.|Department of Oncology, University of Lausanne, Lausanne, Switzerland.
authors.forename: Johanna A
authors.initials: JA
authors.lastname: Joyce
mesh_terms: D006801:Humans; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D016186:Receptor, Macrophage Colony-Stimulating Factor / Q000037:antagonists & inhibitors / Q000235:genetics; D059016:Tumor Microenvironment / Q000187:drug effects / Q000276:immunology
chemical_list: D016186:Receptor, Macrophage Colony-Stimulating Factor